Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory FLT3-mutated AML”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02984995
What this trial is testing

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Who this might be right for
Leukemia, Myeloid, Acute
Daiichi Sankyo Co., Ltd. 37
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)Ended earlyNCT05028751
What this trial is testing

Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Kronos Bio 24
Early research (Phase 1)WithdrawnNCT05330377
What this trial is testing

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Who this might be right for
Acute Myeloid Leukemia
Ayman H Qasrawi
Large-scale testing (Phase 3)UnknownNCT04716114
What this trial is testing

SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

Who this might be right for
Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 315
Not applicableStudy completedNCT04691648
What this trial is testing

Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Who this might be right for
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Korea, Inc. 33
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Testing effectiveness (Phase 2)WithdrawnNCT03324243
What this trial is testing

Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory FLT3-mutated AML
Arog Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06235801
What this trial is testing

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
M.D. Anderson Cancer Center 40
Not applicableStudy completedNCT05193448
What this trial is testing

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Who this might be right for
Refractory AMLRelapsed Adult AMLFLT3-TKD Mutation+1 more
French Innovative Leukemia Organisation 177
Early research (Phase 1)Looking for participantsNCT07137637
What this trial is testing

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Hangzhou Polymed Biopharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03793478
What this trial is testing

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 65
Testing effectiveness (Phase 2)Study completedNCT01892371
What this trial is testing

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
FLT3 Gene Mutation NegativeFLT3 Internal Tandem Duplication PositiveRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center 73
Testing effectiveness (Phase 2)Study completedNCT02530476
What this trial is testing

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Who this might be right for
LeukemiaAcute Myeloid Leukemia
M.D. Anderson Cancer Center 17
Early research (Phase 1)Active Not RecruitingNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Testing effectiveness (Phase 2)Study completedNCT03170895
What this trial is testing

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 5
Testing effectiveness (Phase 2)Study completedNCT03730012
What this trial is testing

ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Global Development, Inc. 11
Large-scale testing (Phase 3)Not Yet RecruitingNCT05876832
What this trial is testing

XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 312